Citigroup
CLYM

Citigroup’s Climb Bio CLYM Stock Holding History

Citigroup’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.7K Sell
5,794
-4,537
-44% -$26.2K ﹤0.01% 4614
2025
Q4 		$41.3K Sell
10,331
-319,217
-97% -$767K ﹤0.01% 4639
2025
Q3 		$662K Sell
329,548
-1,282,339
-80% -$2.38M ﹤0.01% 3424
2025
Q2 		$2M Sell
1,611,887
-238,231
-13% -$296K ﹤0.01% 2652
2025
Q1 		$2.26M Buy
1,850,118
+1,827,387
+8,039% +$2.96M ﹤0.01% 2587
2024
Q4 		$40.9K Buy
22,731
+1,314
+6% +$4.75K ﹤0.01% 5135
2024
Q3 		$109K Buy
21,417
+19,785
+1,212% +$140K ﹤0.01% 4728
2024
Q2 		$11.6K Buy
+1,632
New +$10.9K ﹤0.01% 5111
2022
Q3 		– Sell
-53
Closed – – 6411
2022
Q2 		$0 Sell
53
-371
-88% -$1.75K ﹤0.01% 6745
2022
Q1 		$4K Sell
424
-1,335
-76% -$12.5K ﹤0.01% 5919
2021
Q4 		$18K Buy
1,759
+953
+118% +$14.2K ﹤0.01% 5422
2021
Q3 		$14K Buy
+806
New +$16.7K ﹤0.01% 5389

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Citigroup's CLYM Position: Q1 2026 in Review

Citigroup reduced its Climb Bio (CLYM) stake by 44% in Q1 2026, selling an estimated $26.2K and leaving 5,794 shares worth $39.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4614.

Citigroup first reported a position in CLYM in Q3 2021 and has held it in 12 quarters since. The position peaked at $2.26M in Q1 2025. 80 funds tracked by Wall St. Rank hold CLYM as of Q1 2026.

  • Citigroup held 5,794 shares of Climb Bio worth $39.7K as of Q1 2026.
  • Citigroup sold 4,537 Climb Bio shares in Q1 2026, an estimated $26.2K.
  • Climb Bio made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4614 holding.
  • Citigroup first reported a position in Climb Bio in Q3 2021 and has held it in 12 quarters since.
  • Citigroup's Climb Bio position peaked at $2.26M in Q1 2025.
  • 80 funds tracked by Wall St. Rank held Climb Bio as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.